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Objective. To describe the clinical characteristics and radiological ﬁndings in two patients with subacute encephalitis associated
withelevatedserumvoltage-gatedpotassiumchannelantibody(VGKCAb)andantithyroperoxidase(TPO)antibody.CaseReports.
Case 1: 63-year-old woman was admitted for altered mental status and possible seizure activity. The video EEG showed marked
bifrontal and bitemporal slow wave activity, and several electrographic seizures. MRI brain showed hyperintensity in the bilateral
hippocampal areas. She was positive for VGKCAb and anti-TPO antibodies. She was treated with steroids, IVIG, plasma exchange,
and azathioprine. After 8 months, she had marked improvement in her memory and seizures. Case 2: 61-year-old woman was
admitted for video EEG monitoring of unclassiﬁed seizure and cognitive function decline. Video EEG monitoring showed mild
diﬀuse slowing but no epileptiform discharges. MRI of the brain showed mild hyperintensity in bilateral hippocampal areas and
signiﬁcant atrophy in the frontotemporal lesion. Anti-TPO antibody and VGKCAb were positive. She was treated with steroids,
plasma exchange and azathioprine. After 9 months, she had marked improvement in her memory and seizures. Conclusion.
Autoimmune subacute encephalitis appears to be an underdiagnosed entity. It is important to screen patients with subacute
encephalitis for anti-TPO antibody and VGKCAb, particularly in the presence of seizures. Immunosuppressive therapy appears
to be eﬀective in treating this entity.
1.Introduction
Subacute encephalopathies are neurological and systemic
diseases causing impairment of consciousness insidiously
over weeks or months. Hashimoto’s encephalitis (HE)
is a neurological disorder associated with elevated lev-
els of antithyroperoxidase (TPO) antibody, antithyroglob-
ulin (anti-TG), antiNH2-terminal of a-enolase (NAE)
antibody or anti thyrotropin antibodies. HE responds
to treatment with steroids or plasma exchange and
has a good prognosis [1, 2]. Voltage-gated potassium
channel antibody (VGKCAb)-associated encephalitis is
a paraneoplastic or nonparaneoplastic disorder charac-
terized by amnesia, delirium, and seizures with good
response to intravenous immune globulin (IVIG), plasma
exchange, and steroids [3–7]. We present 2 patients
with subacute encephalitis who were positive for both
antibodies.
2.CaseReport
2.1. Case 1. 63-year-old, right-handed woman admitted
for altered mental status and possible seizure activity.
Seizure activity involved twitching of right face, a ﬂexion
motion of the elbow and stiﬀening of the arm, lasting
around 20 seconds. She also had one episode of gener-
alized tonic clonic seizure. She had a hypomanic state,
visual hallucinations, short-term memory problems, loss of
social inhibition and history of multiple falls. Past medical
history was signiﬁcant for untreated hypothyroidism. On
examination, the patient was oriented to person only. She
had receptive aphasia and perseveration. Gait was ataxic.
The video EEG showed marked bifrontal and bitemporal
slowing with electrographic seizures originating from the
left temporal lobe. Treatment with levetiracetam resulted
in initial improvement. Worsening in 3 days required the
addition of valproic acid. MRI brain showed hyperintensity2 Case Reports in Medicine
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Figure 1:MRIﬁndingsintwocasesofimmunotherapyresponsiveautoimmunesubacuteencephalitis.BrainMRIofPatient1((a),(b))with
immunotherapy responsive voltage-gated potassium channel antibody and antithyroperoxidase antibody-associated subacute encephalitis
illustrates increased signal in the bilateral medial temporal lobes on T2 ﬂuid attenuated inversion recovery (T2 FLAIR) sequences ((a) initial
image). Follow up image after 8 months (b) was unchanged. Brain MRI of case 2 illustrates increased signal in the bilateral medial temporal
lobes on T2 FLAIR ((c) initial image) and after 13 months (d) shows its resolution; T1 with contrast sequence ((e) initial image) shows
bilateral temporal atrophy and after 13 months (f) showing persistent bilateral frontotemporal atrophy.
on T2 ﬂair images in the bilateral hippocampal areas, right
more than left (Figure 1). CSF showed 10 white blood cells
(WBCs), glucose 49, and protein 44. Her CSF protein 14-3-
3 and herpes simplex virus polymerase chain reaction (HSV
PCR)werenegative.Serumparaneoplasticpanelwaspositive
for VGKCAb of 6.21 (reference range (RR): ≤0.02nmol/L).
Her serum thyroid stimulating hormone (TSH) was 6.35
(RR: = 0.35–5.00mcu/ml) and antiTPO antibodies were 142
(RR: = 0–35iu/ml). Serum mean sodium was 135 ranging
from 128 to 140mmol/L. Cancer work up was negative (CT
chest, abdomen and pelvis, mammogram, colonoscopy and
whole body PET scan).
She was treated with synthroid 50mcg daily and IV
methylprednisone 1000mg daily for 5 days followed by IVIG
and plasma exchange with no improvement in mental status.
She was discharged on prednisone and azathioprine. At 8
months follow up, she had marked improvement in her
memory, seizures, and walking. VGKCAb was reduced from
6.21 to 0.86nmol/L and antiTPO antibody had gone down
from 142 to 32.4iu/ml. Repeat MRI 8 months after the initial
MRI was unchanged.
2.2. Case 2. 61-year-old right-handed woman was admitted
for video EEG monitoring of unclassiﬁed seizure. She had
6 months history of frequent, brief episodes of fearful
waking, associated with stiﬀness and moving her right arm
towards her body, grabbing her elbow and asking repeatedly
“Help me. Help me. Where are they?” The patient’s family
reported a decline in the patient’s cognitive functions over
the last few months and a tendency to talk aloud to
herself. She had been recently diagnosed with syndrome
of inappropriate antidiuretic hormone (SIADH) which was
treated with demeclocycline. On examination the patient
was oriented to person only. She had word ﬁnding diﬃculty
and mild-moderate cognitive linguistic deﬁcits in areas of
attention, memory, complex reasoning, and problem solving
tasks. Gait was ataxic. Video EEG monitoring showed mild
diﬀuse slowing but no epileptiform discharges. She was
started on levetiracetam with a signiﬁcant decrease in seizure
frequency. MRI of the brain showed mild hyperintensity
in bilateral hippocampal areas on T2 ﬂair sequences and
signiﬁcant atrophy in the frontotemporal lesion (Figure 1).
CSF analysis showed 50,500 red blood cells (RBCs), 87Case Reports in Medicine 3
Table 1: Comparison of reported cases of subacute encephalitis associated with voltagegated potassium channel antibody (VGKCAb) and
antithyroperoxidase (TPO).
Reference
no./age/sex Seizure type
Initial S.
sodium
(meq/l)
Serum
VGKC Ab
level
(nmol/L)
Other
antibodies
MRIΨ EEGΦ
Response to
immune
therapy∗
Outcome∗∗
Follow
up
MRI∗∗∗
Case 1/63/F CPS, GTCS 128 6.21 TPO, 142 MTS (R > L) F,T,E Good (1, 2, 3) M, S R( r i g h t ) ,
N
Case 2/61/F Frontal lobe seizure
(CPS), GTCS 121 0.13 TPO, 474 MTS, A D, B Good (1, 3) M R
Anti-TG,102
[7]/49/F Probable CPS 127 1.42 TPO, 45 MTS D, T Good (1) M R
[7]/65/M CPS GTC 120 3.30 TPO, 118;
GAD65, 0.09
MTS D Good (1) M R
[5]/36/F GTCS NA 1.038 TPO NN A § Spontaneous
resolution
Good NB
ΨMTS = Bilateral mesial temporal high signal, A = bilateral frontotemporal atrophy, N = Normal.
ΦD = Diﬀuse slowing, E = bitemporal epileptiform discharges, B = Frontal beta activity, T = bitemporal slowing, F = bifrontal slowing.
∗1 = Intravenous steroids, 2 = Intravenous immunoglobulin (IVIG), 3 = Plasma exchange (PLEX), 4 = Azathioprine, 5 = Rituximab, 6 = Mycophenolate
mofetil.
∗∗M = Memory deﬁcits, B = Behavioral changes, S = Seizures.
∗∗∗H = Hippocampal atrophy, R = Resolution of high signals, NB = Normal at baseline, N = new lesion in the left medial temporal lobe.
§NA = Data not available.
WBCs, glucose 59, and protein 77. Her CSF protein 14-3-3
and HSV PCR were negative. AntiTPO antibody (474iu/ml),
antithyroglobulin (102 [RR = 0–40iu/ml]) antibody, and
VGKCAb (0.13nmol/L) were elevated. Cancer work up was
negative. She was started on valproic acid and high-dose
IV methylprednisone and, within 3 to 4 days, the patient
showed signiﬁcant seizure control with slight improvement
in cognition and memory. Her antiTPO antibody decreased
to474iu/ml.Shewasreadmitted2monthslaterforincreased
seizure frequency,myoclonic jerks, and worsening cognition.
She received 5 cycles of plasma exchange with no change in
cognition. The patient was discharged on prednisone and
azathioprine. Follow up at 9 months showed no seizure
activity and marked improvement in mental status with
some deﬁcits in short-term memory. Her SIADH resolved.
Repeat MRI, 13 months after the initial MRI, showed
persistent atrophy in frontotemporal region but resolution
of the hyperintense lesions in the bilateral hippocampal
areas (Figure 1). VGKCAb level decreased from 0.13 to
0.01nmol/L and antithyroglobulin decreased from 102 to
53iu/ml after 15 months on immunotherapy.
3. Discussion
Nonparaneoplastic limbic encephalitis (LE) has been
reported in association of both antiTPO antibody and
VGKCAb in 2 patients by Thieben et al. [7] and 1 patient by
McKnight et al. [5]( Table 1). Similarly, both of our patients
had elevated VGKCAb, and antiTPO antibody. Clinical
features of both are similar to CJD including seizures,
behavioral and psychiatric manifestations, movement
disorders, and coma [2, 3]. Resemblance in presentation
of both antibody syndromes makes it hard to identify
primary antibody causing LE. VGKCAbrelated LE has been
associated with levels as low as 0.03nm/L [6]. Both of our
patients had VGKCAb levels signiﬁcantly higher than 0.03.
Anti-NAE autoantibodies have been found to be a speciﬁc
marker for HE in 44% of patients [8]. We did not check
our patients for Anti-NAE autoantibodies. Hyponatremia is
often seen in VGKCAbrelated LE [2, 3, 7]. Our ﬁrst patient
had variable sodium, with levels as low as 128. The second
patientwasdiagnosedwithSIADHrequiringdemeclocycline
treatment. The sodium abnormalities resolved along with
their encephalitis. Brain MRIs in patients with VGKCAb
are reported to have hyperintensity in the hippocampus or
amygdala[3].InHE,thepatternisofatrophyandsometimes
white matter hyperintensity. Our ﬁrst patient’s scan was
more suggestive of the pattern reported in VGKCAb. Patient
2 had fronto-temporal atrophy, more suggestive of HE
[9], although there was a subtle increase in intensity in
the hippocampus in FLAIR images, more suggestive of
those reported in VGKCAb [3, 5, 7]. VGKCAb has been
associated with cancer (lung, breast, prostrate, thymoma and
hematological malignancy) in some patients [6, 10]. Most of
the cancers presented within 4–6 months after presentation
of limbic encephalitis (range, 1–48 months) [7]. None of
our patients had any evidence of cancer at 12–15 months
follow up. The presence of cancer indicates poor prognosis
for recovery.
Treatment options include intravenous steroids, intra-
venous immunoglobulin or plasma exchange for acute
presentations followed by maintenance immune therapy
(oral prednisone, IVIG, or immunosuppressants) [3–7].
Treatment may have early response or may take 3–8 weeks
before any improvement in cognition. Patient 2 had mild
immediate improvement in cognition and memory follow-
ing intravenous steroids and later following plasma exchange
while patient 1 did not show any early improvement.
Both of our patients had slow, progressive improvement in
their cognition and memory without any relapse while on4 Case Reports in Medicine
prolonged steroids and azathioprine. Clinical improvement
in both of our patients was associated with a decline in
the levels of VGKCAb and antiTPO antibody. MRI lesions
were unchanged in patient 1 at 8-month follow up and
resolved in patient 2 at 13-month follow up, indicating
that it may take 9 months or more for the MRI lesions to
clear up [11]. Patients with VGKCAbrelated LE may have
a relapsing course [3]. Patient 2 had relapsed when treated
only with a short course of steroids. VGKCAb and antiTPO
antibody-related encephalitis is a treatable entity with good
prognosis ranging from 60%–92% [3, 7]. Autoimmune
subacuteencephalitisappearstobeanunderdiagnosedentity
[12]. In our opinion, coexistence of antiTPO antibody and
VGKCAb indicates abroaderautoimmune abnormality,with
multiple autoantibodies still undiscovered. Patients with a
diagnosis of HE or VGKCAb may be tested for a broader
range of antibodies in order to clarify this relationship. Anti-
TPO antibodies may not be pathogenic [13]. In this case, the
presence of other autoantibodies should be sought in cases
of subacute encephalitis in patients with antiTPO antibodies
alone. As our knowledge of the so-called paraneoplastic
antibodies expands, we may ﬁnd that the autoantibodies
actually responsible for the encephalitis might be quite
diﬀerent from those that have already been discovered.
AntiTPO antibodies or VGCKAb may actually represent an
epiphenomenon rather than a true causative factor.
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